Literature DB >> 2936766

Influence of food on midazolam absorption.

L D Bornemann, T Crews, S S Chen, S Twardak, I H Patel.   

Abstract

The influence of food on the absorption of midazolam, a new benzodiazepine derivative, was investigated in 18 healthy volunteers in a four-way, randomized, crossover study with a one-week washout period between treatments. Single 15-mg oral doses of midazolam were administered one hour before, with, and one hour after a standard meal as well as under fasting conditions (control). Following serial blood sampling over the next 24-hour period, midazolam plasma concentrations were determined by gas chromatography and mass spectrometry for pharmacokinetic evaluation. The maximum plasma concentration (Cmax), time of maximum concentration (tmax), lag time prior to absorption (tlag), area under the plasma concentration-time curve (AUC), and elimination rate constant of midazolam and 1-hydroxymethylmidazolam were determined. Significant changes in these parameters were not found when midazolam was taken one hour before or with a meal as compared with the control condition. Significant changes in the Cmax, tmax, and AUC parameters for both midazolam and its metabolite were seen when midazolam was ingested one hour after a meal: There was a delayed and reduced rate of absorption as well as a small reduction in the extent of absorption. Thus, ingestion of midazolam within one hour after a meal may result in a delay in the onset of the pharmacologic effect. These changes may be of some clinical significance in that they may potentially delay the onset of sleep.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936766     DOI: 10.1002/j.1552-4604.1986.tb02903.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.

Authors:  J M Scavone; D J Greenblatt; J E Goddard; H Friedman; J S Harmatz; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Authors:  Pierre-Eric Juif; Margaux Boehler; Yves Donazzolo; Shirin Bruderer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

3.  The recovery time-course of CYP3A after induction by St John's wort administration.

Authors:  Hiromitsu Imai; Tsutomu Kotegawa; Kimiko Tsutsumi; Takuya Morimoto; Nobuoki Eshima; Shigeyuki Nakano; Kyoichi Ohashi
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

4.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

Review 5.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 6.  Pharmacokinetics of the newer benzodiazepines.

Authors:  P D Garzone; P D Kroboth
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

7.  The pharmacokinetics of midazolam in patients with congestive heart failure.

Authors:  I H Patel; P P Soni; E K Fukuda; D F Smith; C V Leier; H Boudoulas
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

8.  Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions.

Authors:  Scott R Penzak; Kristin H Busse; Sarah M Robertson; Elizabeth Formentini; Raul M Alfaro; Richard T Davey
Journal:  J Clin Pharmacol       Date:  2008-04-16       Impact factor: 3.126

9.  In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).

Authors:  Georgina Meneses-Lorente; Stephen Fowler; Elena Guerini; Karey Kowalski; Edna Chow-Maneval; Li Yu; Francois Mercier; Mohammed Ullah; Kenichi Umehara; Andreas Brink; Vincent Buchheit; Elke Zwanziger; Alex Phipps; Nassim Djebli
Journal:  Invest New Drugs       Date:  2021-08-21       Impact factor: 3.850

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.